ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand.
|Articles|September 7, 2017
- Pharmaceutical Commerce - September/October 2017
Cold Chain 2017 Directory
Advertisement
Save
Articles in this issue
about 9 years ago
Patient data saves livesabout 9 years ago
MDM’s growing role in running healthcare businessesabout 9 years ago
The power of strategic data standardizationabout 9 years ago
2017 Cold Chain Outlookabout 9 years ago
Is the opioid crisis a national emergency?about 9 years ago
It’s time for an industry guideline on patient support servicesabout 9 years ago
A conversation with Greg Flynn, Ashfield Healthcare USabout 9 years ago
LogiPharma meeting highlights digital transformationabout 9 years ago
Drug development in rare diseasesAdvertisement
Related to this article
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
GEODIS' David Frouin explains why securing the lane outranks sustainability and why full corridor models are the cold chain trend to watch.
At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal discusses reusable shippers, PCM innovation and AI's role in cold chain risk.
CSafe's Aaron Mantia explains how lane, temperature range, duration and product cost shape thermal protection choices for bulk air cargo.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how automation cuts human touches, enforces quarantine and consolidates cold storage.
PAXAFE's Mark Talens explains why real-time visibility starts with process redesign and how it speeds cold chain disposition decisions.
At LogiPharma USA 2026, Cold Chain Technologies' Anthony "TJ" Rizzo discusses cold chain expertise gaps and how data tools are reshaping the profession.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
2
2026 Brought Progress on Drug Prices. What Will It Take to Improve Patient Access in 2027?
3
Does Your Pharmaceutical WMS Grow with You?
4
Why the Best Drug Launches Are Built to Adapt
5